Kavanagh J J, Edwards C L, Freedman R S, Finnegan M B, Balat O, Tresukosol D, Burk K, Loechner S, Hord M, Franklin J L
Section of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Gynecol Oncol. 1995 Jul;58(1):106-9. doi: 10.1006/gyno.1995.1191.
Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy. A fundamental difficulty is the development of tumor resistance to platinum compounds. Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines. Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m2 but was later reduced to 40 mg/m2 because of excessive thrombocytopenia. Nine patients required red cell transfusions during therapy. Cycles were repeated every 21-35 days (median cycle length 28 days). No objective responses were observed. Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer.
尽管采用了多模式治疗，但上皮性卵巢癌的长期生存仍然存在问题。一个基本难题是肿瘤对铂类化合物产生耐药性。已开发出在体外和体内对铂耐药细胞系均显示活性的类似物。洛铂（D - 19466），一种第三代化合物，在卡铂和顺铂耐药细胞系中显示出显著活性。对17例可评估的铂难治性卵巢癌患者给予洛铂。该药物最初以50mg/m²的剂量给药，但后来由于血小板减少过多而减至40mg/m²。9例患者在治疗期间需要输注红细胞。每21 - 35天重复一个周期（中位周期长度28天）。未观察到客观缓解。洛铂对铂耐药的上皮性卵巢癌无活性。
